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Abstract   28 
Proteinase-activated receptor 2 (PAR2) is a G protein-coupled receptor involved in 29 
metabolism, inflammation, and cancers. It is activated by proteolysis, which exposes a 30 
nascent N-terminal sequence that becomes a tethered agonist. Short synthetic peptides 31 
corresponding to this sequence also activate PAR2, while small organic molecules 32 
show promising PAR2 antagonism. Developing PAR2 ligands into pharmaceuticals is 33 
hindered by a lack of knowledge of how synthetic ligands interact with and 34 
differentially modulate PAR2. Guided by PAR2 homology modeling and ligand 35 
docking based on bovine rhodopsin, followed by cross-checking with newer PAR2 36 
models based on ORL-1 and PAR1, site-directed mutagenesis of PAR2 was used to 37 
investigate the pharmacology of three agonists (two synthetic agonists and trypsin-38 
exposed tethered ligand) and one antagonist for modulation of PAR2 signaling. 39 
Effects of 28 PAR2 mutations were examined for PAR2-mediated calcium 40 
mobilization and key mutants were selected for measuring ligand binding. Nineteen 41 
of twenty-eight PAR2 mutations reduced the potency of at least one ligand by >10-42 
fold. Key residues mapped predominantly to a cluster in the transmembrane (TM) 43 
domain of PAR2, differentially influence intracellular Ca2+ induced by synthetic 44 
agonists versus a native agonist, and highlight subtly different TM residues involved 45 
in receptor activation. This is the first evidence highlighting the importance of the 46 
PAR2 TM region for receptor activation by synthetic PAR2 agonists and antagonists. 47 
The trypsin-cleaved N-terminus that activates PAR2 was unaffected by the same 48 
residues as synthetic peptides, challenging the widespread practice of substituting 49 
peptides for proteases to characterize PAR2 physiology.    50 
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 53 
Chemical compounds studied in this article 54 
GB88 (PubChem CID: 73755230); GB110 (PubChem CID: 49843508); 2f-LIGRLO-55 
NH2 (PubChem CID: 10395438) 56 
 57 
Abbreviations: CHO-hPAR2, Chinese Hamster Ovary cells transfected with human 58 
PAR2; EC50, molar concentration that produces 50% of the maximum response of an 59 
agonist; ECL2, extracellular loop 2; Fluo-3, {[2-(2-{2-[Bis(carboxymethyl)amino]-5-60 
(2,7-dichloro-6-hydroxy-3-oxo-3H-xanthen-9-yl)phenoxy}ethoxy)-4-61 
methylphenyl](carboxymethyl)amino}acetic acid; GB88, 5-isoxazoyl-Cha-Ile-62 
spiroindene-1,4- piperidine; GPCRs, G Protein-Coupled Receptors; G-protein, 63 
guanosine monophosphate protein; HBSS, Hank’s Balanced Salt Solution; IC50, molar 64 
concentration of an antagonist that inhibits 50% of a known concentration of agonist 65 
activity; iCa2+, intracellular calcium ion; OPLS, Optimized Potentials for Liquid 66 
Simulations; PARs, Proteinase-Activated Receptors; pEC50, negative logarithm of 67 
EC50; SEM, standard error of the mean; pIC50, negative logarithm of IC50; SEM, 68 
standard error of the mean; TM, transmembrane; WT, wild type  69 
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Introduction    70 
Proteinase-activated receptors are unique G protein-coupled receptors (GPCRs) 71 
in being self-activated following proteolytic action at their extracellular N-terminus 72 
by mainly serine proteases (Adams et al., 2011; Dery et al., 1998; Coughlin et al., 73 
2003). This exposes a new N-terminus, the ‘tethered ligand’, which folds back and 74 
binds intramolecularly to induce intracellular signaling via poorly understood 75 
mechanisms (Barry et al., 2006; Ramachandran et al., 2012). Four PARs have been 76 
identified and numbered in order of their discovery (Coughlin et al., 2000).  77 
PAR2 is activated by serine proteases such as trypsin and tryptase but, unlike 78 
other PARs, not by thrombin (Adams et al., 2011; Barry et al., 2006; Bohm et al., 79 
1996; Ramachandran et al., 2012). PAR2 can also be activated by synthetic peptide 80 
agonists that mimic the N-terminal sequence of the tethered ligand (e.g. SLIGRL-NH2 81 
(rodent), SLIGKV-NH2 (human), 2f-LIGRLO-NH2 (potent derivative), P2pal-18S 82 
and 2at-LIGRL-PEG3-hdc (both lipid-tethered derivatives) (Barry et al., 2006; 83 
Hollenberg et al., 1997; Maryanoff et al., 2001; Sevigny et al., 2011; Flynn et al., 84 
2013; Boitano et al., 2014) and by small molecule agonists (e.g. AC-55541, AC-85 
264613 (Seitzberg et al., 2008)). Our group has identified two non-peptide ligands 86 
that were selective for PAR2 over PAR1 and other GPCRs, the agonist GB110 and 87 
antagonist GB88 (Barry et al., 2010; Suen et al., 2012, Suen et al., 2014). GB110 had 88 
identical agonist potency with 2f-LIGRLO-NH2 in inducing Ca2+ release in multiple 89 
cell types. In addition, both GB110 and 2f-LIGRLO-NH2, as well as proteases like 90 
trypsin and tryptase but not thrombin, were inhibited by PAR2 antagonist GB88. In 91 
recent years PAR2 has been implicated in many in vitro and in vivo models of 92 
inflammatory diseases as well as cancer and metabolic disorders (Adams et al., 2011; 93 
Badeanlou  et al., 2011; Boitano et al., 2015; Lin et al., 2015; Ramachandran et al., 94 
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2012; Shi et al., 2013; Vesey et al., 2013; Yau et al., 2013). The PAR2-selective 95 
antagonist GB88 has shown beneficial effects in vivo in rodent models of 96 
inflammation including paw odema (Suen et al., 2012; Suen et al., 2014), collagen-97 
induced arthritis (Lohman et al., 2012a), experimental colitis (Lohman et al., 2012b) 98 
and diet-induced obesity (Lim et al., 2013). 99 
Ligand interactions with PAR2 have previously been reported to involve the 100 
extracellular N-terminus and extracellular loop 2 (ECL2) (Al-Ani et al., 1999; 101 
Compton et al., 2000; Compton et al., 2002; Ma et al., 2013). A common 102 
polymorphism at position 240 potentiates PAR2 activation by certain ligands, but not 103 
others (Compton et al., 2000; Ma et al., 2013). Also, site-directed mutagenesis 104 
indicated that by removing the glycosylation site of rat PAR2 ECL2 by mutating 105 
N222A reduced sensitivity to both trypsin and PAR2 activating peptide (Compton et 106 
al., 2002). Mutations at positions 231-233 reportedly reduce agonist potency by ≤ 107 
100-fold (Al-Ani et al., 1999). Each of these studies focused on the ECLs but did not 108 
examine a role for residues within the transmembrane (TM) domain of PAR2. 109 
As crystal structures for class A GPCRs human A2A, turkey b1 and human 110 
P2Y12 (Warne et al., 2011; Xu et al., 2011; Zhang et al., 2014) show extensive 111 
interactions between a bound agonist and residues in TM regions, we hypothesized 112 
the TM region of PAR2 is important in influencing ligand-induced receptor 113 
activation. Based on a homology structural model of PAR2 (Fig. 1) derived by 114 
sequence alignment with a crystallographically characterized GPCR, 28 PAR2 115 
mutants were constructed to investigate whether specific amino acids in the receptor 116 
affected PAR2 activation by endogenous (trypsin induced) and synthetic agonists (2f-117 
LIGRLO-NH2 and GB110). 2f-LIGRLO-NH2 was selected as the most commonly 118 
used peptide agonist for PAR2, while GB110 was selected as a potent non-peptidic 119 
 7 
agonist and we have previously studied this agonist in detail.REF We also selected 120 
antagonist GB88 due to its reported antagonist properties both in vitro and in 121 
vivo.REF The effect of each PAR2 mutation on ligand-induced downstream signaling 122 
was assessed to elucidate the impact of these residues on PAR2 activation. Herein, a 123 
cluster or ‘hot spot’ of receptor residues that affect the activation of PAR2 by the 124 
tested ligands has been identified. Whether other structurally diverse PAR2 agonists 125 
or antagonists are affected by similar ‘hot spot’ residues remains to be determined, 126 
but this study provides valuable new insights for rational design of future PAR2 127 
agonists and antagonists. These prospective drugs might be used to selectively 128 
modulate PAR2-mediated signaling and influence the pathophysiological function of 129 
PAR2 in disease. 130 
 131 
Methods 132 
Sequence alignment of human PAR2 with bovine rhodopsin crystal structure (pdb: 133 
1U19) and Homology Modeling 134 
The human PAR2 sequence obtained from Swiss-Prot (accession number P55085) 135 
was aligned with the bovine rhodopsin crystal structure (pdb: 1U19, monomer) 136 
sequence using the PAM-250 matrix, which aligns the sequence based on 137 
conservation of charged, bulky aliphatic, or aromatic residues. Alignment was refined 138 
manually by examining structurally conserved regions and assessing likely TM 139 
regions using the approach of Bissantz et al (Bissantz et al., 2003). The seven TM 140 
helices were identified based on conserved residues in each putative TM helix. The 141 
alignment was used to develop coordinates for TM regions using ModellerTM, with a 142 
disulfide bond constraint between C148 (TM3) and C226 (ECL2). Loop regions were 143 
developed using Modeller TM and the rhodopsin template. The model was refined to 144 
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remove steric clashes by a minor modification of the minimisation and molecular 145 
dynamics protocol above (the Newton minimisation algorithm was not performed 146 
because of the large number of atoms). In this minimisation protocol, TM backbone 147 
atoms were kept tethered to maintain TM helicity. The resulting conformation was 148 
used for ligand docking.  149 
 150 
Homology Modeling based on nociceptin/orphanin FQ/ORL-1 receptor (pdb: 4EA3, 151 
TM sequence identity = 29%) and PAR1 (pdb: 3VW7, TM sequence identity = 44%) 152 
Modeller 9v10 (Sali and Blundell 1993) was used to build homology models 153 
of PAR2 based on ORL-1 and PAR1 crystal structures, after aligning the PAR2 154 
sequence with the templates using Jalview (Waterhouse et al., 2009). The models with 155 
the lowest discrete optimization protein energy (DOPE) score were further optimized 156 
for the ECL2 loop refinement in Prime (version 3.1, Schrödinger, LLC, New York, 157 
NY, 2012) using the truncated-Newton energy minimization (OPLS_2005 force field 158 
with restrained helical backbone). The final models were refined using the protein 159 
preparation wizard in Schrödinger to optimize hydrogen bond networks and for a 160 
restrained energy minimization (OPLS_2005 force field and heavy atom movement 161 
<0.5 Å). 162 
 163 
Ligand docking  164 
All ligands were constructed in 2D sdf format using ChemDraw. Conversion 165 
from 2D into 3D co-ordinates was performed using LigPrep in Maestro 166 
(Schrödinger). OPLS (Optimized Potentials for Liquid Simulations) force field was 167 
applied during ligand structural optimization and the protonation status of ligands was 168 
set for physiological conditions. Ligand docking was performed using GOLD (ccdc 169 
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v3.2) with default docking settings. GOLD applies a genetic algorithm during docking 170 
simulation and each ligand conformation is encoded analogously as evolution of a 171 
population of possible solutions via genetic operators to a final population. A radius 172 
of 10Å around residue F300 or F6.48 (Ballesteros Weinstein numbering scheme) 173 
(Ballesteros and Weinstein, 1995) was defined as the putative ligand-binding site. 174 
Ligands were docked in 10 independent poses (population size 100). Operator 175 
weights for mutations, migration and crossover were 95, 10 and 95 respectively. To 176 
account for partial flexibility of PAR2, residues (F243, F155, F300, Y156, M159, 177 
L307, L330, D228, F251, L246) were defined and allowed to move according to the 178 
Chi rotamer library developed in the docking run (Lovell et al., 2000). Docked poses 179 
were ranked using the internal Gold score (Jones et al., 1997) and manual inspection 180 
of interactions with receptor. Final analysis and visualisation of protein-ligand 181 
interactions were performed using Pymol. To cross-check the results from the 182 
Rhodopsin-derived PAR2 model, the ligands were also subsequently docked into 183 
PAR2 homology models built from ORL-1 and PAR1 crystal structures. The PAR2 184 
homology structures and ligand docking protocols using these models are detailed 185 
elsewhere (Perry et al, 2015).  186 
 187 
Cell culture and reagents 188 
Cell culture reagents were purchased from Invitrogen (Carlsbad, CA) and Sigma 189 
Aldrich (St. Louis, MO). Flp-In Chinese Hamster Ovary (CHO)-K1 cells (Invitrogen) 190 
were maintained in Ham’s F12 media containing 10% FBS and 2 mM L-glutamine in 191 
5% CO2 at 37 oC. PAR2 peptide agonist (2f-LIGRLO-NH2), non-peptide agonist 192 
(GB110) and non-peptide antagonist (GB88) were synthesized in-house (Barry et al., 193 
2010). A23187 was purchased from Sigma-Aldrich, Fluo-3 AM and Pluronic F127 194 
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from Sapphire Bioscience (NSW, Australia), and assay plates from Corning (New 195 
York, NY). 196 
 197 
Vector construction and transfection 198 
cDNA encoding human PAR2 with a C-terminal FLAG epitope (DYKDDDDK) 199 
was subcloned into a pcDNA5/FRT vector (Life technologies/invitrogen) using a 200 
BamHI restriction enzyme site. Site directed mutagenesis was performed using a 201 
QuickChange kit (Stratagene) according to manufacturer’s instructions to generate 202 
individual receptor mutants (Table 1). Primer sequences are available upon request. 203 
All constructs were sequenced at the Australian Genomic Research Facility (St Lucia, 204 
Australia). Stably expressing cells were generated following manufacturer’s 205 
instructions. PAR2-pcDNA5/FRT constructs were cotransfected with Flp-recombinase 206 
expression vector pOG44 (1:9 pcDNA5/FRT:pOG44) into Flp-In CHO-K1 cells using 207 
Lipofectamine 2000. Stable polyclonal populations of transfected cells were selected 208 
in media containing 600 µg/mL hygromycin B. 209 
 210 
Crude membrane preparation and Western blot analysis 211 
Expression of wildtype and each PAR2 mutant was assessed as described (Adams 212 
et al., 2011; Adams et al., 2012). Crude membrane preparations were collected by 213 
isotonic cell shock and mechanical disruption followed by ultracentrifugation 214 
(100,000 g for 60 min at 4 °C) to pellet the membrane fraction. Fractions were 215 
resuspended in lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% 216 
Triton X-100 (v/v) and 1× protease inhibitor cocktail (Roche)) before quantification 217 
using a BCA assay kit from Pierce (Thermo Fisher Scientific, Scoresby, Australia). 218 
Equal amounts of membrane fractions were separated by SDS-PAGE and transferred 219 
 11 
to nitrocellulose membrane. Membranes blocked in Odyssey blocking solution from 220 
LiCor (Millennium Science, Surrey Hills, Australia) were incubated with goat anti-221 
PAR2 N19 (Santa Cruz) and mouse anti-Pan Cadherin (Millipore) antibodies 222 
overnight at 4 °C. Membranes were washed and incubated with species appropriate 223 
IRdye 700 or 800 secondary antibodies at ambient temperature for 45 min before 224 
washing to minimize non-specific signals followed by scanning on an Odyssey 225 
infrared imaging system (LiCor).  226 
 227 
Flow cytometry analysis   228 
 Cell surface expression of wildtype and each PAR2 mutant was assessed as 229 
described (Adams et al., 2012). Cells (2.5 x 105) dissociated non-enzymatically from 230 
cell culture flasks were washed and stained with goat anti-PAR2 N19 antibody (2 µg / 231 
1 x 106 cells) in buffer (2% BSA in PBS) for 30 min at 4°C. Cells were washed and 232 
stained with AlexaFluor 488-conjugated donkey anti-goat secondary antibody before 233 
analysis on a Beckman Coulter FC500 flow cytometer. Events were counted (20,000) 234 
and mean fluorescence intensity (MFI) was used to assess cell surface PAR2 after 235 
subtracting MFI values from cells incubated only with secondary antibody. 236 
Competitive ligand binding and calcium mobilization assays are well established 237 
methods reported in Supporting Material. 238 
 239 
Competitive binding assay 240 
Assays were performed as described (Hoffman et al., 2012). Cells were seeded 241 
overnight in a 384-well plate at a density of 24000 cells per well. On the day of 242 
experiment, media was aspirated and cells were washed with PBS followed by 2% 243 
BSA blocking for 1h at 37°C. After blocking, cells were simultaneously exposed to 244 
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concentrations of 2f-LIGRLO(dtpa)-NH2 and 2f-LIGRLO-NH2 (100 µM) for 15 min. 245 
Cells were washed thrice with PBS supplemented with 20 µM EDTA, 0.01% Tween 246 
and 0.2% BSA. After washings, cells were incubated with 40 µl of DELFIA 247 
enhancement solution (Perkin Elmer) for 90 min. Fluorescence was determined with 248 
TRF analysis (Pherastar FS, BMG Labtech): 340 nm excitation followed by 400 µs 249 
delay before a 400 µs 615 nm emission.  250 
 251 
Intracellular calcium mobilization 252 
Cells were grown to 80% confluence. Prior to experiment, cells were seeded 253 
overnight in 96-well black wall, clear bottom, plates at ~5 x 104 cells per well. On the 254 
day of the experiment, supernatant was removed and cells were incubated in dye 255 
loading buffer (Hank’s Balanced Salt Solution (HBSS) with 4 µM Fluo-3, 0.04% 256 
pluronic acid, 1% fetal bovine serum (FBS) and 2.5 mM probenecid) for 1 h at 37 °C. 257 
Cells were washed twice with HBSS and transferred to a FLIPR Tetra plate reader 258 
(Molecular Device, Sunnyvale CA) for agonist injection and fluorescence 259 
measurements. PAR2 agonists were added 10 s after reading commenced at various 260 
concentrations and fluorescence was measured in real time using excitation 480 nm 261 
and emission 520 nm. HBSS was prepared in-house, all other reagents were from 262 
Invitrogen (Carlsbad), plates from Corning. Calcimycin (A23187, Sigma Aldrich) 263 
was used to measure maximum fluorescence, with individual results normalized 264 
accordingly. 265 
 266 
Statistical analysis 267 
Data were analyzed in GraphPad Prism (GraphPad Software, San Diego, CA) 268 
using ANOVA or Student's t-test with values as mean ± SEM (n≥3). Data are 269 
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presented as the mean of the entire data set. Significance was determined by 270 
P<0.05. When plotted in concentration-response curve, intracellular Ca2+ response 271 
was normalized against highest concentration of respective agonist in CHO-272 
hPAR2WT. Concentration-response curves were fitted in GraphPad Prism with a 273 
standard Hill slope of 1 (three-parameter fit). 274 
 275 
  276 
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Results 277 
Homology Structural Models of PAR2  278 
A PAR2 structural homology model was generated by sequence alignment of 279 
human PAR2 to the crystal structure of bovine rhodopsin (pdb: 1U19; Palczewski et 280 
al., 2000), at a time when this was the only reported GPCR crystal structure. The 281 
PAR2 homology model was submitted to SwissModel portal 282 
(http://swissmodel.expasy.org/) for quality and stereochemical properties check. The 283 
assessment of model quality-related parameters (such as Qmean6 score, dfire energy 284 
and Ramachandran statistics) were compared with the original crystal structure of the 285 
bovine rhodopsin (1U19). The PAR2 homology model gave a RMSD value of 0.37 286 
compared to the bovine rhodopsin. Qmean6 score (PAR2 0.41, Rhodopsin 0.40) is a 287 
linear combination of six structural descriptors and a higher Qmean6 (range between 288 
0 and 1) reflects strong reliability of the model. DFire (PAR2 -465.5; Rhodopsin -289 
557.8) is an all-atom statistical potential term used to assess non-bonded atomic 290 
interactions in the protein model. The homology model of PAR2 produced comparable 291 
scores for these two components, relative to the template from which they were 292 
constructed. Furthermore, all residues in the rhodopsin based homology model were 293 
located in the favored and allowed φ-ψ regions from the Ramachandran plot analysis, 294 
suggesting that the constructed homology model was both energetically and 295 
stereochemically reliable.  296 
 297 
In silico docking of three ligands in a PAR2 homology structural model 298 
Interactions between PAR2 and three synthetic ligands were examined in silico 299 
(Fig. 1A). Synthetic ligands used in silico were the two PAR2 agonists, 2f-LIGRLO-300 
NH2 (Kanke et al., 2005; McGuire et al., 2004) and GB110 (Barry et al., 2010), as 301 
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well as the PAR2 antagonist GB88 (Suen et al., 2012) (Fig. 1B-D). All three ligands 302 
were also experimentally assessed in an intracellular calcium mobilization assay. 303 
 304 
 305 
FIGURE 1. Putative ligand-receptor interactions. (A) 2f-LIGRLO-NH2, GB110, and 306 
GB88 were each docked into a homology structural model of PAR2 generated from 307 
the crystal structure of bovine rhodopsin. The docking result was then cross-checked 308 
by docking into PAR2 models generated from ORL-1 and PAR1. Residues are colored 309 
according to their importance in the three models (magenta, RHO/ORL-1/PAR1), two 310 
models (orange, RHO/ORL-1; green, RHO/PAR1) or the RHO model only (black). 311 
(B-D) Residues predicted to mediate PAR2 interaction with (B) 2f-LIGRLO-NH2, (C) 312 
GB110, and (D) GB88.  313 
 314 
Modeling predicted that both agonists would occupy a similar binding region 315 
within the TM domain of PAR2. 2f-LIGRL-NH2 rather than 2f-LIGRLO-NH2 was 316 
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docked since the ornithine does not contribute significantly to agonist potency and 317 
can confound docking orientations due to its charged sidechain finding alternative 318 
binding sites on its own (Kanke et al., 2005; McGuire et al., 2004). The similar 319 
components of 2f-LIGRLO-NH2 and GB110 (2-furoyl vs isoxazole, Leu vs Cha, Ile 320 
vs Ile) were predicted to dock into pockets formed by TM3 (Y156, Y160), TM5 321 
(F243, L246, V250) and TM6 (N304, L307, V308) (Fig. 1B,C). The other ligand 322 
components were predicted to orient slightly differently for the two agonists. R4 in 323 
2f-LIGRLO-NH2 was predicted to orient towards residues at the top of TM6 (Y311) 324 
and TM7 (Y326) as well as ECL2 (D228) (Fig. 1B). However, the terminal 325 
aminomethyl piperidine group of GB110 was predicted to project between TM2 326 
(Y82) and TM7 (L330) (Fig. 1C). The antagonist GB88 docked in a similar binding 327 
site, but its orientation was reversed with the isoxazole in a small pocket formed by 328 
Y82, F155 and L330 (Fig. 1D). Its cyclohexylalanine oriented into space between 329 
TM6 (Y307) and TM7 (Y326), while isoleucine oriented towards F155. The bulky 330 
spiroindenepiperidine occupied a hydrophobic site surrounded by Y156, Y160, F243, 331 
F251 and N304 (Fig. 1D). These predicted sites suggested a cluster of amino acids 332 
within the TM region of PAR2 that might be expected to influence ligand potencies 333 
and efficacies.  334 
 Following completion of this study, crystal structures of human 335 
nociceptin/orphan FQ receptor (4EA3) (Thompson et al., 2012) and the antagonist 336 
bound PAR1 receptor (3VW7) (Zhang et al., 2012) provided alternative templates for 337 
also constructing homology models of PAR2. When the above ligands were docked 338 
into either of these new models of PAR2 based on the different template crystal 339 
structures, the key residues inferred from the rhodopsin-based model of PAR2 (Y82, 340 
L151, F155, Y156, F243, L307, Y311, Y326, L330) were also found in the ORL-1 341 
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derived model of PAR2, while Y156, Y160, E232, F243, L307, Y311, Y326, L330 342 
were also found in the PAR1-based model of PAR2. In particular, both models 343 
predicted 2f-LIGRLO-NH2 to make several polar interactions with residues Y311, 344 
D228ECL2, whereas Y156 from the ORL-1 model was also predicted to form polar 345 
contact with the ligand. The rest of the residues were mainly predicted to contribute to 346 
hydrophobic and aromatic interactions. The major difference seen was the position of 347 
the 2f group, which was docked within a pocket between TM2 and TM7 in the ORL-1 348 
based model, while in the PAR1 based model this group was docked between TM5 349 
and TM6 (Perry et al., 2015). Of the residues shown ahead to cause >30-fold 350 
reduction in receptor activation, only Y296 and N304 were not predicted from the 351 
new homology models of PAR2. Interestingly, those two residues are the deepest in 352 
the TM 7-helix bundle and might be indirectly impacted through knock-on or 353 
conformational changes during receptor activation. The new models of PAR2 thus 354 
supported the above predictions based on the bovine rhodopsin derived PAR2 355 
homology structure, while presenting some new clues for further refinement of the 356 
PAR2 model.  357 
 Based on these predicted ligand-binding sites, 18 PAR2 TM residues (Y82, F128, 358 
L151, F155, Y156, Y160, F243, L246, V250, F251, Y296, S303, N304, L307, Y308, 359 
Y311, Y326, L330) and an ECL2 residue (D228) were chosen for mutagenesis to 360 
investigate the experimental effect of these mutations on ligand-induced downstream 361 
signaling. Two additional ECL2 residues, E232 and Q233, were also selected for 362 
mutation on the basis of previous studies (Al-Ani et al., 1999), giving a total of 21 363 
amino acids to be mutated. Fig. 1 displays these residues revealing where they cluster 364 
within or near the TM region of PAR2, thereby forming putative ‘hot spots’ in PAR2 365 
that might dictate agonist and antagonist ligand activity. 366 
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 367 
Mutation of PAR2 in stably expressing cell lines 368 
Site directed mutagenesis generated expression constructs encoding the relevant 369 
amino acid mutated to alanine (Y82, L151, D228, E232, Q233, F243, L246, V250, 370 
F251, Y296, S303, L307, Y308), chosen to inform the importance of larger sidechains 371 
for space-filling; to leucine (Y160) or tryptophan (L330), to test the importance of 372 
aromaticity; or with 6 residues mutated to both small alanine and bulkier hydrophobic 373 
leucine (F128, F155, Y156, N304, Y311, Y326). A construct encoding the double 374 
mutant E322A/Q233A was also generated to allow comparison with a previous study 375 
on rat PAR2 (Al-Ani et al., 1999) to give a total of 28 PAR2 mutant expression 376 
constructs. To examine the impact of these mutations on ligand-induced signaling, 377 
CHO-K1 cells were generated that stably expressed each of the 28 mutants or 378 
wildtype PAR2. The impact of each mutation on structural integrity of PAR2 and its 379 
cell surface expression was assessed using Western blot and flow cytometry. Western 380 
blot analysis revealed that each PAR2 was expressed at consistent levels as a 381 
characteristic ladder of bands from ~30-80 kDa (Fig. 2A, upper panel), as described 382 
(Adams et al., 2012). Similarly, flow cytometry demonstrated that cell surface 383 
expression was comparable for wildtype and each mutant PAR2 (Fig. 2A, lower 384 
panel). These data indicated structurally integrity and PAR2 surface expression on 385 
CHO-K1 cells. Importantly, cells transfected with vector failed to produce any 386 
significant signal in response to synthetic agonists 2f-LIGRLO-NH2 and GB110 or 387 
tethered ligand formed by trypsin cleavage, in contrast with cells transfected with 388 
wildtype PAR2 (Fig. 2B-D). This indicates that calcium mobilization in transfected 389 
cells was PAR2 mediated.  390 
 391 
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 392 
FIGURE 2. PAR2 expression and activation. (A) Expression and cell surface levels 393 
of wild type and mutant PAR2 in CHO-K1 cells. Upper: Western blot analysis, 394 
performed on equal amounts of crude membrane preparations using an anti-Flag 395 
antibody, shows that PAR2 wildtype and mutants were expressed at similar levels. 396 
Lower: Flow cytometry analysis on non-permeabilized cells using anti-PAR2 N19 397 
antibody confirmed that wildtype and PAR2 mutants were expressed at the cell 398 
surface. Levels ranged within +/- 10% of the wildtype receptor for 15 of the mutants 399 
with another 8 within +/- 20%. Cell surface levels of PAR2-F128A, E232A-Q233A, 400 
S303A, L307A and V308A were within +/- 30% of wildtype PAR2. (B-D): 401 
Intracellular Ca2+ mobilization by PAR2 agonists in CHO-PAR2 wild type vs CHO-402 
hPAR2 empty vector. All three agonists (B, 2f-LIGRLO-NH2; C, GB110; D, Trypsin) 403 
stimulated intracellular calcium release in CHO cells transfected with wild type PAR2 404 
(circle) but failed to induced any response in CHO cells transfected with empty vector 405 
(square). Data points = means of 3 experiments in triplicates (n=3), bars = S.E. 406 
 407 
  408 
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Effect of PAR2 mutations on synthetic agonist potencies 409 
The real impact of PAR2 mutations on signaling was experimentally assessed by 410 
intracellular calcium release induced by escalating doses of 2f-LIGRLO-NH2 and 411 
GB110. The pEC50 and fold changes relative to wildtype PAR2 are shown in Table 1. 412 
Four mutations induced enormous reductions (>100 fold) in ligand potencies, three 413 
located in the TM domain (Y82A, Y156A, Y326A) and the fourth in ECL2 (D228A) 414 
(Table 1). All four mutations had similar effects on potency of both agonists 2f-415 
LIGRLO-NH2 and GB110 (Fig. 3A-D). Six other TM mutations (Y156L, F251A, 416 
Y296A, N304A, N304L, Y311A) along with ECL2 mutation E232A also induced 417 
substantial (>10 fold) reductions in signaling by both agonists (Table 1). Overall, 19 418 
of 28 mutant PAR2 cell lines revealed ≥10 fold attenuation in activity for at least one 419 
agonist (Fig. 3E). When analyzed by scatter plot, there was a high correlation between 420 
mutation-induced fold changes in activity of 2f-LIGRLO-NH2 versus GB110 (Fig. 421 
3F), indicating that these ligands were affected by a similar set of residues of PAR2.  422 
 
 
 
Table 1 Effect of PAR2 mutations on potencies of agonists inducing Ca2+ release in PAR2 
expressing CHO-K1 cells 
  2f-LIGRLO-NH2 (n=4) GB110 (n=4) Trypsin (n=4) 
PAR2 Mutation  pEC50 Fold pEC50 Fold pEC50 Fold 
Wild Type 7.4 ± 0.2 
 
7.5 ± 0.1 
 
8.7 ± 0.1 
 Vector inactive 
 
inactive 
 
inactive 
 Y82A < 4 >2000 < 4 >2000 7.6 ± 0.4 13 
F128A 6.8 ± 0.2 4 6.7 ± 0.3 6 8.1 ± 0.2 4 
F128L 6.4 ± 0.1 11 6.5 ± 0.2 9 8.5 ± 0.2 1 
L151A 7.3 ± 0.2 1 7.2 ± 0.5 2 8.3 ± 0.1 3 
F155A 7.0 ± 0.3 3 6.5 ± 0.2 10 8.2 ± 0.2 3 
F155L 6.3 ± 0.1 12 6.7 ± 0.1 6 8.3 ± 0.3 2 
Y156A 5.3 ± 0.2 110 5.1 ± 0.2 250 7.9 ± 0.1 6 
Y156L 6.2 ± 0.1 16 5.7 ± 0.2 59 8.0 ± 0.1 5 
Y160L 6.6 ± 0.2 6 6.6 ± 0.2 7 7.8 ± 0.1 8 
D228A 5.3 ± 0.2 140 5.3 ± 0.2 170 7.8 ± 0.2 7 
E232A 6.1 ± 0.4 18 6.1 ± 0.3 28 7.9 ± 0.1 7 
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Q233A 7.2 ± 0.1 2 8.5 ± 0.2 0.1 8.2 ± 0.1 3 
E232AQ233A 6.6 ± 0.1 6 8.2 ± 0.1 0.2 8.5 ± 0.1 2 
F243A 6.4 ± 0.2 11 6.7 ± 0.2 7 8.5 ± 0.2 2 
L246A 6.3 ± 0.2 13 6.5 ± 0.1 9 8.0 ± 0.2 4 
V250A 7.2 ± 0.3 2 6.3 ± 0.4 17 8.3 ± 0.2 2 
F251A 5.9 ± 0.1 28 6.2 ± 0.1 18 8.0 ± 0.2 5 
Y296A 5.7 ± 0.2 51 6.0 ± 0.2 30 7.5 ± 0.1 17 
S303A 6.7 ± 0.3 5 6.6 ± 0.2 7 8.4 ± 0.2 2 
N304A 5.9 ± 0.1 29 6.1 ± 0.2 27 7.6 ± 0.2 12 
N304L 5.8 ± 0.1 40 5.8 ± 0.1 50 7.1 ± 0.1 37 
L307A 6.8 ± 0.2 4 5.8 ± 0.1 54 8.4 ± 0.2 2 
V308A 7.2 ± 0.3 2 7.4 ± 0.2 1 8.4 ± 0.2 2 
Y311A 5.6 ± 0.1 62 5.8 ± 0.1 44 8.2 ± 0.1 3 
Y311L 7.0 ± 0.2 2 7.3 ± 0.3 2 8.0 ± 0.1 5 
Y326A 5.0 ± 0.2 240 5.3 ± 0.1 160 7.8 ± 0.2 7 
Y326L 6.7 ± 0.2 6 6.2 ± 0.1 19 7.9 ± 0.1 5 
L330W 7.2 ± 0.3 2 7.3 ± 0.3 1 8.2 ± 0.2 3 
n = number of independent experiments 
pEC50 = -log(EC50) 
	 	pEC50 ± S.D., Fold Change = EC50 Mutant/EC50 Wild Type 
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FIGURE 3. Concentration response curves of 2f-LIGRLO-NH2 and GB110 on 424 
various PAR2 mutants. Intracellular calcium release induced by PAR2 activation was 425 
plotted against various concentrations of 2f-LIGRLO-NH2 (black) and GB110 (blue). 426 
(A-D) Mutations (A, Y82A; B, Y156A; C, D228; D, Y326A) have similar effects on 427 
both PAR2 agonists. Data points = means of 3 experiments in triplicates (n=3), bars = 428 
S.E. (E,F) Summary of influences of PAR2 residues on synthetic agonist potencies of 429 
2f-LIGRLO-NH2 vs GB110. (E) Effect of mutation on agonist potencies. Fold 430 
changes calculated by EC50 of PAR2 mutant over EC50 of PAR2 wild type (WT). (F) 431 
Correlation study of effects of mutation on agonist potencies. R2 = 0.97.  432 
 433 
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CHO cells expressed with wild type or vectors only or 8 mutated PAR2 were 434 
selected for measuring agonist affinity. Y156A, D228A and Y326A were chosen due 435 
to their significant impact on PAR2-induced calcium release (Table 1). Five 436 
neighboring mutants (F155A, Y156L, Y160L, Y326L, L330W) were also selected. A 437 
receptor saturation assay was used to calculate Kd for 2f-LIGRLO(dtpa)-NH2 on each 438 
cell line (Fig. 4). Control experiments with PAR2 WT gave Kd 0.67 µM and the 439 
tagged peptide failed to bind to CHO cells not expressing PAR2. This suggested 440 
specific binding to human PAR2. Similar to the negative control, Y156A, D228A and 441 
Y326A all failed to give any measurable saturation, indicating that labeled peptide 442 
was not able to selectively bind to the mutated receptor expressed. In contrast, each of 443 
the remaining 5 mutants was able to produce a Kd ~3-5 fold weaker than wild type. 444 
 445 
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 446 
FIGURE 4. Representative saturation curves for 2f-LIGRLO(dtpa)-NH2 specific 447 
binding to wild-type and mutant PAR2 receptors. Specific binding was measured by 448 
incubating CHO cells expressed with various PAR2 mutants with different 449 
concentrations of 2f-LIGRLO(dtpa)-NH2 and 2f-LIGRLO-NH2 (100 µM). Kd was 450 
calculated from 3 or more independent experiments. 451 
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Effects of PAR2 mutations on trypsin potency 453 
 The agonist potency was measured for trypsin on the same 28 mutated PAR2 454 
transfected CHO cell lines in Table 1. Only four mutations (Y82A, Y296A, N304A, 455 
N304L) caused > 10-fold reductions in agonist potencies (Fig. 5A-C) and all were in 456 
the TM region of PAR2, indicating the importance of the TM region in protease-457 
mediated PAR2 activation. However, in contrast to the two synthetic agonists, most 458 
mutations examined induced < 10-fold reductions in trypsin-induced agonist potency 459 
(Fig. 5D). This suggested that the tethered ligand was not as susceptible to the same 460 
mutations as the two synthetic agonists. In support of this conclusion, there was no 461 
significant correlation between effects of mutants on calcium mobilization induced by 462 
trypsin vs by each synthetic agonist (Fig. 5E,F). 463 
 464 
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 465 
FIGURE 5. Summary of influences of PAR2 residues on serine protease trypsin. (A-466 
C) Concentration response curves of trypsin on various PAR2 mutants. Intracellular 467 
calcium release induced by PAR2 activation was plotted against various 468 
concentrations of trypsin. Mutations (A, Y82A; B, Y296A; C, N304A, N304L) all 469 
lowered potencies of trypsin by >10 fold. Data points = means of 3 experiments in 470 
triplicates (n=3), bars = S.E. (D) Effects of mutation on trypsin potencies. Fold 471 
changes calculated by EC50 of PAR2 mutant over EC50 of PAR2 wild type (WT). (E-F) 472 
Correlation studies of effects of mutations on trypsin against (E) 2f-LIGRLO-NH2 or 473 
(F) GB110. 474 
 475 
 476 
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Effects of PAR2 mutation on antagonist potency  477 
 GB88 is a small molecule reported to effectively antagonize calcium release in 478 
human cells by all PAR2 agonists, including the peptides SLIGRL-NH2, SLIGKV-479 
NH2, 2f-LIGRLO-NH2, the peptidomimetic GB110, and proteases like trypsin, 480 
tryptase and cathepsin S (Barry et al., 2010; Suen et al., 2012; Zhao et al., 2014a). In 481 
order to determine the impact of mutation of PAR2 residues on GB88 potency, cells 482 
were first incubated with escalating doses of GB88 and stimulated with trypsin at 483 
EC80 determined from Table 1. The pIC50 and fold change (mutant versus wildtype 484 
PAR2) values are listed in Table 2. GB88 could not be tested against CHO-485 
hPAR2Y82A cells, as the agonist response generated by trypsin was too small to 486 
produce a significant signal-to-noise ratio. Overall, seven mutants derived from 487 
changes at 5 positions (Y156, D228, N304, L307, Y326) on PAR2 were found to 488 
inactivate GB88 (<40% max inhibition) antagonism of trypsin-induced intracellular 489 
calcium release (Fig. 6). In addition, L151A and F243A mutations reduced potency of 490 
GB88 by greater than 10-fold (Table 2).  491 
 492 
 493 
FIGURE 6. Concentration response curves of GB88 antagonism on various PAR2 494 
mutants. Dose response curves of GB88 inhibition against trypsin (EC80) on various 495 
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mutants (A, Wild type; B, Y156; C, D228; D, N304; E, L307; F, Y326). Data points = 496 
means of 3 experiments in triplicates (n=3), bars = S.E.  497 
 498 
Table 2. PAR2 mutants reducing GB88 antagonism of trypsin-induced iCa2+ release in CHO-
hPAR2 cells 
  Max. inhibition       
(% ± SEM) 
GB88 (n ≥ 3) EC80 Trypsin  
(nM)   pIC50 ± SEM IC50 (uM) Fold 
Wild Type 80 ± 2 6.3 ± 0.1 0.5 1 20 
Y82A* n.d. n.d. n.d. n.d. - 
F128A 80 ± 4 6.0 ± 0.2 1 2 45 
F128L 70 ± 2 5.5 ± 0.2 3 6 30 
L151A 65 ± 3 5.7 ± 0.1 22 44 30 
F155A 70 ± 5 6.0 ± 0.1 1 2 30 
F155L 60 ± 2 5.6 ± 0.3 2 4 230 
Y156A 30 ± 5 inactive - - 70 
Y156L 25 ± 4 inactive - - 70 
Y160L 70 ± 5 6.3 ± 0.3 0.5 1 60 
D228A 20 ± 2 inactive - - 130 
E322A 70 ± 3 5.8 ± 0.1 1.5 3 80 
Q233A 80 ± 2 6.3 ± 0.1 0.5 1 50 
E322AQ233A 80 ± 4 6.3 ± 0.1 0.5 1 30 
F243A 60 ± 3 5.2 ± 1.2 7 14 60 
L246A 80 ± 4 6.5 ± 0.2 0.3 0.6 240 
V250A 90 ± 4 7.0 ± 0.1 0.9 1.8 40 
F251A 60 ± 6 5.7 ± 0.5 2 4 70 
Y296A 90 ± 1 6.5 ± 0.1 0.3 0.6 90 
S303A 80 ± 2 6.0 ± 0.1 1 2 25 
N304A 40 ± 5 inactive - - 230 
N304L 70 ± 4 5.6 ± 0.3 3 6 230 
L307A 25 ± 6 inactive - - 30 
V308A 80 ± 3 6.2 ± 0.2 0.7 1.4 20 
Y311A 90 ± 2 6.8 ± 0.1 0.2 0.4 110 
Y311L 70 ± 5 7.5 ± 0.2 0.03 0.06 40 
Y326A 30 ± 8 inactive - - 60 
Y326L 25 ± 4 inactive - - 40 
L330W 95 ± 1 6.4 ± 0.1 0.4 0.8 30 
n = number of independent experiment, % ± Standard Error of Mean 
Fold Change = IC50 mutant / IC50 Wild Type 
*GB88 was not tested in Y82A due to small agonist response 
inactive – GB88 failed to inhibit >40% of agonist response 
EC80 Trypsin – Trypsin concentration used to induce PAR2 activation 
pIC50 = -logIC50 
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GB88 antagonism of 2f-LIGRLO-NH2 and GB110 induced activation of PAR2 499 
 Analysis of the effect of increasing concentrations of GB88 on Ca2+ release, induced by 500 
escalating doses of 2f-LIGRLO-NH2 and GB110, revealed that on CHO-hPAR2WT, GB88 501 
caused a rightward horizontal shift of agonist concentration-response curves (Fig. 7A,B) and 502 
by Schild plots, which had linear slopes of 0.95 ± 0.1 and 1.15 ± 0.14 respectively (Fig. 503 
7C,D). Slight reductions of the maxima were also observed. It could be caused by the short 504 
assay timeframe, preventing the system to reach true equilibrium and leads to subsequent 505 
depression of maxima. Incubation time was reduced in order to investigate potential kinetic 506 
artifact (Charlton and Vauquelin 2010; Kenakin et al., 2006), however, GB88 was inactive 507 
against both 2f-LIGRLO-NH2 and GB110 in the iCa2+ assay without pre-incubation (Fig. 508 
8A,B). Furthermore, reduction of incubation time from 30 min to 5 min failed to recover the 509 
maxima (Fig. 8C,D).   510 
 511 
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 512 
FIGURE 7. Antagonism of GB88 in CHO-hPAR2 wild type. (A-B) GB88 is a competitive 513 
PAR2 antagonist against (A) 2f-LIGRLO-NH2 and (B) GB110. (C-D) Schild plot for 514 
antagonist GB88 against (C) 2f-LIGRLO-NH2 and (D) GB110. Calculated pA2 values for 515 
GB88 against 2f-LIGRLO-NH2 and GB110 was 6.2 ± 0.2 and 6.5 ± 0.2 respectively. Data 516 
points = means of 3 experiments in triplicates (n=3), bars = S.E. 517 
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 518 
FIGURE 8. Kinetic study of GB88 antagonism of PAR2 in CHO-hPAR2 wild type. (A-B) 519 
Increasing concentrations of GB88 were added either 5 min prior to agonist addition or 520 
simultaneously with agonist and measured for intracellular calcium release. GB88 was only 521 
able to inhibit (A) 2f-LIGRLO-NH2 (10 µM) or (B) GB110 (10 µM) after 5 min pre-522 
incubation. (C-D) Reduction in pre-incubation time failed to reduce maxima reduction. Pre-523 
incubation time of GB88 was shortened from our normal exposure of 30 min to just 5 min 524 
prior to agonist addition. No significant changes in maxima reduction as a result of shorter 525 
antagonist incubation time. Data points are means of at least 3 experiments in triplicate (n≥3), 526 
bars = S.E. 527 
 528 
 As mentioned earlier, most of the mutations caused a similar potency reduction for each 529 
of the two synthetic agonists, with the exception of F155A, V250A and L307A. These three 530 
mutants reduced GB110 potency to a much greater extent (10-, 17- and 54-fold respectively) 531 
than did 2f-LIGRLO-NH2 (3-, 2- and 4-fold respectively). These differences in potency 532 
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reductions suggested subtly different interactions between the two synthetic ligands and 533 
PAR2, so we similarly inspected corresponding effects on the antagonist GB88. As L307A 534 
was ruled out due to its inactivation of the antagonist (Table 2, max inhibition 25%), further 535 
experiments were performed on the remaining two mutants (F155A, V250A). When IC50 536 
values of GB88 were calculated by increasing its concentration against a fixed agonist 537 
concentration, no significant difference was observed against each of the 2 agonists in each of 538 
the 3 cell lines (WT, F155A, V250A) (Fig. 9A, B). However, as shown in Fig. 10 this was 539 
not true when a Schild plot analysis was performed.  F155A showed similar results as wild 540 
type-PAR2 for antagonism by GB88 against the two synthetic agonists, i.e. increasing 541 
concentrations of GB88 resulted in horizontal shifts in concentration-response curves of both 542 
2f-LIGRLO-NH2 (Fig. 9C) and GB110 (Fig. 9D). In contrast to WT and F155A, V250A 543 
showed distinct differences in affecting each synthetic agonist. When GB88 was used to 544 
inhibit 2f-LIGRLO-NH2, reduction of maxima was significantly greater at >1 µM (Fig. 9E), 545 
whereas a similar maxima reduction was not observed when GB110 was used as agonist (Fig. 546 
9F). This indicated that the V250A mutation turned GB88 into an insurmountable antagonist 547 
against 2f-LIGRLO-NH2, but not against GB110. 548 
 549 
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 550 
FIGURE 9. Antagonism of GB88 in mutants. (A,B) PAR2 antagonist GB88 inhibits iCa2+ 551 
release induced in CHO transfected with wild type PAR2 or mutants (F155A, V250A) by (A) 552 
2f-LIGRLO-NH2, or (B) GB110. (A) GB88 IC50s against 2f-LIGRLO-NH2 are WT, 2 µM ± 553 
0.4 µM; F155A, 2.4 µM ± 0.6 µM; V250A, 1 µM ± 0.3 µM. (B) GB88 IC50s against 2f-554 
LIGRLO-NH2 are WT, 2.2 µM ± 0.6 µM; F155A, 1.8 µM ± 0.6 µM; V250A, 0.8 µM ± 0.3 555 
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µM. (C,D) GB88 is a competitive PAR2 antagonist against (C) 2f-LIGRLO-NH2 and (D) 556 
GB110 in F155A. (E,F) GB88 is an insurmountable antagonist against (E) 2f-LIGRLO-NH2 557 
but a surmountable antagonist against (F) GB110 in V250A. (G,H) Schild plot for antagonist 558 
GB88 against 2f-LIGRLO-NH2 and GB110 in F155A and V250A. (G) Calculated pA2 values 559 
for GB88 against 2f-LIGRLO-NH2 and GB110 in F155A was 5.8 ± 0.15 and 6.5 ± 0.2, 560 
respectively. (H) Calculated pA2 values for GB88 against 2f-LIGRLO-NH2 and GB110 in 561 
V250A was 6.3 ± 0.15 and 6.7 ± 0.1 respectively Data points = means of 3 experiments in 562 
triplicates (n=3), bars = S.E. 563 
 564 
 Schild slope analysis further validated the differences between F155A and V250A. 565 
F155A produced a linear gradient of 0.81 ± 0.1 for 2f-LIGRLO-NH2 and 0.96 ± 0.1 for 566 
GB110, indicating GB88 is a competitive antagonist against both synthetic agonists in F155A 567 
PAR2 (Fig. 9G). In comparison, V250A produced steeper Schild slopes of 1.3 ± 0.1 (2f-568 
LIGRLO-NH2) and 1.6 ± 0.1 (GB110) (Fig. 9H). A Schild slope >1 can indicate insufficient 569 
equilibration time, and GB88 may not have attained equilibrium at lower concentrations, thus 570 
changing the gradient of the Schild plot. A steep slope can also imply binding cooperativity 571 
of an antagonist, where the V250A mutation enables binding of more than one molecule of 572 
GB88. In either case, V250A mutation significantly changed how the receptor interacts with 573 
the agonist/antagonist. F155A also reduced the pA2 of GB88 against 2f-LIGRLO-NH2 from 574 
6.2 (wild type) to 5.8, but the pA2 value of GB88 against GB110 remained unchanged at 6.5, 575 
while V250A had no significant changes in pA2 of GB88 against both agonists.  576 
 577 
  578 
 35 
Discussion and Conclusions579 
 This is the first detailed analysis of the importance of amino acids in the transmembrane 580 
region of PAR2 for dictating intracellular Ca2+ release induced by PAR2 ligands. This study 581 
monitored effects of PAR2 mutations on calcium release, a signaling pathway commonly used 582 
for PAR2 research and previously shown to dictate inflammatory responses of PAR2 agonists 583 
2f-LIGRLO-NH2, GB110, trypsin and the pathway selective anti-inflammatory antagonist 584 
GB88, both in vitro and in vivo in rodents (Suen et al, 2012; Suen et al 2014; Lohman et al, 585 
2012a). This approach was used rather than a competitive binding assay for comparative 586 
ligand affinities for PAR2 because, unlike other GPCRs, there is no orthosteric ligand for 587 
PAR2 that can be used exogenously to compete with, since only proteases are known to 588 
endogenously activate PAR2. Thus, in order to correlate receptor binding with receptor 589 
activity, we instead performed a receptor saturation assay using 2f-LIGRLO(dtpa)-NH2 on 590 
PAR2. Ten cell lines (WT, Vector, 8 mutants) were found to change the observed Kd values 591 
of this exogenous in a similar manner in the receptor saturation assay as in the calcium assay, 592 
strongly supporting the validity of using the calcium functional assay for measuring receptor 593 
mutant effects on ligand binding. 594 
 This study has identified for the first time that the transmembrane region of PAR2 is 595 
crucial for receptor activation by the synthetic ligands described herein, as defined by ligand 596 
binding and by induction of intracellular calcium signaling (Fig. 10). in particular, four 597 
transmembrane mutations (Y82A, Y296A, N304A and N304L) reduced potencies of all three 598 
agonists examined here and highlighted the importance of those residues in PAR2 activation. 599 
Furthermore, we examined 28 mutations of PAR2 and found a cluster of residues defining a 600 
‘hot spot’ within the TM region of the receptor that is critical for PAR2-mediated signal 601 
transduction by these ligands, potentially due to changes in ligand-receptor interactions. Eight 602 
TM mutants (Y82, F155, Y156, F251, Y296, N304, Y311 and Y326) affected both of the two 603 
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synthetic agonists similarly. Three of these residues (Y82, Y156 and Y326), along with 604 
ECL2 residue D228, were the most important for PAR2 activation (> 100 fold) induced by 605 
GB110 and 2f-LIGRLO-NH2. It is interesting to note that these two synthetic agonists did not 606 
give entirely identical responses, with two mutations (V250 and L307) showing significant 607 
differences between the effects of these agonists.  608 
 609 
FIGURE 10. Summary of PAR2 mutations that impact synthetic ligand-induced signaling. 610 
All residues selected for mutagenesis in this study are highlighted in the PAR2 model. 611 
Residues found to affect agonist activity (Table 1) are colored in red (>100 fold), blue (>15 612 
fold) and yellow (<15 fold). 613 
 614 
 This is the first time that PAR2 has been mutated at multiple positions within and around 615 
its transmembrane region. There have only been a few previous reports (Compton et al., 616 
2000; Compton et al., 2002; Ma et al., 2013) of PAR2 mutations at all and they focused only 617 
on one or a few mutations in ECL2 but not in the TM region. The findings here of the 618 
importance of TM region to ligand-induced activation as measured by Ca2+ release are novel 619 
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and demonstrate a significant role of the TM region in PAR2 activation and downstream 620 
signal transduction. This study has also established that PAR2 signaling is similar to other 621 
class A GPCRs, where the TM region has been shown to be crucial for interaction with 622 
agonists and antagonists (Tyndall et al., 2005; Blakeney et al., 2007; Ruiz-Gómez et al., 623 
2010) with strong support from crystal structures and computer models (Deupi and Standfuss, 624 
2011; Nakamura et al., 2013). 625 
 The original ligand binding predictions were derived from a PAR2 homology model 626 
built from rhodopsin some years ago when this was the only class A GPCR with a reported 627 
crystal structure. Following the completion of this study, new crystal structures have become 628 
available for class A GPCRs, including ORL-1 (PDB: 4EA3) (Thompson et al., 2012) and 629 
PAR1 (PDB: 3VW7) (Zhang et al., 2012). The ligands described herein were re-docked into 630 
new homology models built (Perry et al., 2015) from these crystal structures. The PAR1-631 
derived PAR2 model was problematic (despite high sequence similarity) because the bound 632 
ligand vorapaxar was large and believed to distort the structure of PAR1. Vorapaxar does not 633 
bind to PAR2, so the high sequence identity of PAR1 and PAR2 created a problem with an 634 
unusual ligand-binding site being created for PAR2. Nonetheless, the predictions of the 635 
binding modes in both of these two additional models encouragingly overlapped with 40% of 636 
the residues predicted from the rhodopsin-based model, including almost all of the key 637 
residues.  638 
There have been concerns that rhodopsin as a modelling basis may unfairly bias 639 
toward an internal TM binding site, as the rhodopsin receptor itself has a covalently bound 640 
internal ligand. Although it is possible that the docking results from our model have been 641 
influenced by this, recent class A GPCRs have also been shown to share a common TM 642 
binding location as to that in rhodopsin (Congreve et al., 2011), suggesting an internal 643 
binding pocket is not unique to rhodopsin, but common among class A GPCRs. This was 644 
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evidenced further by a recent crystal structure of CCR5 bound to its allosteric inhibitor 645 
maraviroc (Tan et al., 2013). Furthermore, the rhodopsin template has been successfully used 646 
for homology modelling of other GPCRs, such as leukotriene receptor (Dong et al., 2013), 647 
alpha1A receptor (Evers and Klabunde 2005), beta2 adrenoceptor (Costanzi 2008), MT1 and 648 
MT2 receptors (Farce et al., 2008). It is important to note that there are limitations with 649 
homology structures derived from low sequence homology, which has encouraged the 650 
development of GPCR models from different crystal structures. It has been reported that 651 
there is no correlation between sequence identity and model quality (Ratai et al, 2014), and 652 
our use of three PAR2 homology models derived from three different GPCR crystal 653 
structures does highlight a conserved subset of PAR2 residues that warranted mutation.  654 
 Our data has shown that PAR2 activation by two synthetic agonists (2f-LIGRLO-NH2, 655 
GB110) was mainly affected by PAR2 mutations clustered within the TM region, whereas 656 
receptor activation by trypsin was largely unaffected by these mutations. Most mutations on 657 
GPCRs alter ligand activity either (i) directly by altering the specific binding site of the 658 
ligand or (ii) indirectly by changing receptor conformation with a knock-on or induced fit 659 
influence on ligand-receptor interaction. While results of this study alone cannot precisely 660 
unravel the mechanisms of PAR2 activation, it is clear that the synthetic agonists examined 661 
were significantly more susceptible than trypsin to these changes in the TM region of PAR2. 662 
In our opinion, the finding that over 20 amino acids clustered in the TM region of PAR2 663 
strongly influence the actions of three synthetic ligands, but not the trypsin-induced native 664 
ligand, is suggestive of different ligand-binding sites on PAR2. While this ‘hot spot’ within 665 
PAR2 is possibly an allosteric, rather than orthosteric, ligand-binding site, further studies and 666 
indeed PAR2 crystal structures are required to confirm this hypothesis. 667 
  This study has involved a diverse set of PAR2 mutations to probe the differential 668 
effects of a narrow group of synthetic ligands on PAR2-induced calcium release and identifies 669 
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a receptor ‘hot spot’ within the TM region of the receptor that is critical for PAR2-mediated 670 
calcium release by these ligands. Further sets of mutants in the ECL regions and the TM-671 
solvent interface could similarly be used to identify residues important for different tethered 672 
ligands, known to be exposed by the actions of different endogenous proteases (e.g. trypsin, 673 
tryptase, factor VIIa, cathepsin S, elastase, etc). There have been a few other small molecule 674 
agonists (e.g. AC-55541, AC-264613 (Seitzberg et al., 2008)) and antagonists (e.g. ENMD-675 
1068 (Kelso et al., 2006), K14585 (Kanke et al., 2009; McIntosh et al., 2010), C391 (Boitano 676 
et al., 2015)) reported to modulate PAR2 in recent years, as well as many proteases and 677 
peptides (Hollenberg et al., 2014; Zhao et al., 2014b), including some peptides with lipid 678 
appendages (e.g. P2pal-18S (Sevigny et al., 2011), 2at-LIGRL-PEG3-hdc (Flynn et al., 679 
2013)). It is not known where any of these compounds bind on PAR2 and so studies like that 680 
reported here could reveal similar or new receptor ‘hot spots’ required for ligand-induced 681 
PAR2 signaling.  682 
 An additional level of complexity lies in a downstream signaling pathway being 683 
monitored for such studies. Recent identification of biased ligands for PAR2 (Ramachandran 684 
et al., 2014; Suen et al., 2014; Zhao et al., 2014b) suggests that different signaling pathways 685 
may be subtly influenced by only small changes to ligands, which in turn alter interactions 686 
with the receptor. Other studies have shown that mutations in the tethered ligand region of 687 
PAR2 can differentially activate different signaling pathways (e.g. Ca2+, MAPK) 688 
(Ramachandran et al., 2009; Elmariah et al., 2014), different proteases can induce different 689 
signaling profiles (Elmariah et al., 2014; Zhao et al., 2014a; Zhao et al., 2014b), different 690 
small molecule ligands can bias signaling to different outcomes (Goh et al., 2009; Hollenberg 691 
et al., 2014), and different cell types and reporter assays can produce different PAR2 692 
signaling. Linking these effects to specific residues in the receptor and specific components 693 
of the ligand, as we have begun to do in this study, can dramatically help improve our 694 
 40 
understanding of the molecular basis of PAR2-directed intracellular signaling and may permit 695 
development of drugs that control different PAR2-mediated signaling pathways in different 696 
physiological and disease settings. This is important because PAR2 (like other GPCRs) has 697 
beneficial and protective physiological effects that may need to be preserved, while 698 
selectively modulating just one or a subset of PAR2-mediated signaling pathways associated 699 
with a particular diseased state may be more desirable. Studies such as this contribute to our 700 
understanding of ligand-induced PAR2 signaling, while future studies are needed to 701 
determine the direct mechanisms employed for activation versus inhibition of different 702 
signaling pathways mediated by the same receptor and different (or even the same) ligands.  703 
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